Drugs / ARCT-2304
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06602531 | Dec 2024 → Jun 2025 | influenza | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARCT-2304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06602531 ↗ |
| Modality | Small activating RNA (saRNA) | “self-amplifying mRNA pandemic influenza (H5N1) vaccine (ARCT-2304)” NCT06602531 ↗ |
| Route | Intramuscular | “Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.” NCT06602531 ↗ |